Your browser doesn't support javascript.
loading
Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan
Cesheng Li; Ding Yu; Xiao Wu; Hong Liang; Zhijun Zhou; Yong Xie; Taojing Li; Junzheng Wu; Fengping Lu; Lu Feng; Min Mao; Lianzhen Lin; Huanhuan Guo; Shenglan Yue; Feifei Wang; Yan Peng; Yong Hu; Zejun Wang; Jianhong Yu; Yong Zhang; Jia Lu; Haoran Ning; Huichuan Yang; Daoxing Fu; Yanlin He; Dongbo Zhou; Tao Du; Kai Duan; Demei Dong; Kun Deng; Xia Zou; Ya Zhang; Rong Zhou; Yang Gao; Xinxin Zhang; Xiaoming Yang.
Affiliation
  • Cesheng Li; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Ding Yu; Chengdu Rongsheng Pharmaceuticals Co., Ltd
  • Xiao Wu; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Hong Liang; Beijing Tiantan Biological Products Co., Ltd
  • Zhijun Zhou; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Yong Xie; Beijing Tiantan Biological Products Co., Ltd
  • Taojing Li; Beijing Tiantan Biological Products Co., Ltd
  • Junzheng Wu; Chengdu Rongsheng Pharmaceuticals Co., Ltd
  • Fengping Lu; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Lu Feng; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Min Mao; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Lianzhen Lin; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Huanhuan Guo; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Shenglan Yue; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Feifei Wang; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Yan Peng; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Yong Hu; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Zejun Wang; Wuhan Institute of Biological Products Co. Ltd
  • Jianhong Yu; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Yong Zhang; Beijing Tiantan Biological Products Co., Ltd
  • Jia Lu; Wuhan Institute of Biological Products Co. Ltd
  • Haoran Ning; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Huichuan Yang; China National Biotec Group Company Limited
  • Daoxing Fu; Beijing Tiantan Biological Products Co., Ltd
  • Yanlin He; Beijing Tiantan Biological Products Co., Ltd
  • Dongbo Zhou; Beijing Tiantan Biological Products Co., Ltd
  • Tao Du; Beijing Tiantan Biological Products Co., Ltd
  • Kai Duan; Wuhan Institute of Biological Products Co. Ltd
  • Demei Dong; Beijing Tiantan Biological Products Co., Ltd
  • Kun Deng; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Xia Zou; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Ya Zhang; Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd
  • Rong Zhou; Beijing Tiantan Biological Products Co., Ltd
  • Yang Gao; Beijing Tiantan Biological Products Co., Ltd
  • Xinxin Zhang; Ruijin Hospital
  • Xiaoming Yang; China National Biotec Group Company Limited
Preprint in English | bioRxiv | ID: ppbiorxiv-437224
Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article
ABSTRACT
To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses. The results show that positive rate of IgG antibody against receptor-binding domain of spike protein (RBD-IgG) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the COVID-19 convalescent plasma donors exceeded 70% for 12 months post diagnosis. The level of RBD-IgG decreases with time, with the titer stabilizing at 64.3% of the initial level by the 9th month. Moreover, male plasma donors produce more RBD-IgG than female, and age of the patients positively correlates with the RBD-IgG titer. A strong positive correlation between RBD-IgG and neutralizing antibody titers is also identified. These results facilitate our understanding of SARS-CoV-2-induced immune memory to promote vaccine and therapy development.
License
cc_by_nd
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Cohort_studies / Observational study / Prognostic study Language: English Year: 2021 Document type: Preprint
Full text: Available Collection: Preprints Database: bioRxiv Type of study: Cohort_studies / Observational study / Prognostic study Language: English Year: 2021 Document type: Preprint
...